Juno Bio, a UK-founded healthtech company focused on women’s health diagnostics, has secured $3.8 million in funding to accelerate its growth and infrastructure expansion. The round was led by Ada Ventures, with participation from Artesian, Entrepreneur First, and Illumina Accelerator.
The funding announcement coincides with a significant operational milestone: the company has opened its first CLIA-certified sequencing laboratory in Oakland, California. This facility represents a key step in Juno Bio’s strategy to scale its clinical operations and bring its precision diagnostics platform closer to American patients and healthcare providers.
Addressing a Gap in Women’s Health
Juno Bio specializes in precision vaginal microbiome testing, targeting a segment of diagnostic medicine that has historically received limited attention and innovation. The company has already distributed over 20,000 tests to patients seeking insight into their reproductive and vaginal health. According to Hana Janebdar, Founder and CEO of Juno Bio, the company’s trajectory reflects growing recognition of the importance of microbiome diagnostics in women’s healthcare.
“Over the past five years, Juno Bio has grown from a pioneering vaginal microbiome test into a clinical platform advancing a new standard of care for women’s health,” Janebdar stated. “We’re incredibly grateful to our investors and partners for their trust in our team and our vision as we move into this next stage of growth.”
Strategic Expansion Plans
The $3.8 million investment will be allocated toward scaling clinical infrastructure, expanding access to microbiome testing services, and advancing women’s health research initiatives. The opening of the Oakland sequencing lab positions Juno Bio to increase testing capacity while maintaining the quality standards required for clinical diagnostics.
The company’s focus on the vaginal microbiome addresses a recognized gap in diagnostic medicine. Microbiome composition plays a significant role in reproductive health outcomes, yet testing and interpretation remain relatively nascent fields compared to other areas of clinical diagnostics. By developing accessible testing platforms and advancing the underlying research, Juno Bio aims to improve diagnostic options available to women and their healthcare providers.
European Context
The funding round highlights the continued vitality of European-founded healthtech companies expanding into North American markets. While Juno Bio originated in the UK, its decision to establish infrastructure in California reflects broader patterns among European biotech and diagnostics firms seeking to scale operations internationally.
The backing from prominent investors including Ada Ventures and Illumina Accelerator underscores growing investor interest in precision diagnostics and women’s health innovation. As European startups increasingly compete in global markets, developments like Juno Bio’s funding and lab opening demonstrate the capacity of UK-based companies to attract capital and build clinically validated platforms that serve international patient populations.